Mirikizumab
Impressive results on a phase 3 trial:
www.prnewswire.com
More than one-half of patients with Crohn’s disease treated with Lilly’s mirikizumab achieved clinical remission at one year, including patients with previous biologic failure
/PRNewswire/ — In Eli Lilly and Company’s (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn’s disease, with or…
www.prnewswire.com
« At one year, clinical remission and endoscopic response were achieved by 54.1% and 48.4% of patients on mirikizumab, respectively. Notably, of the patients who received mirikizumab, 56.7% of…
